ArticleProceedings (Baylor University. Medical Center)2017
Olmesartan-associated enteropathy.
Article in Proceedings (Baylor University. Medical Center), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Olmesartan-Induced Enteritis Mimicking Small Bowel Crohn's Disease.ACG case reports journal · 2026Article
- Olmesartan-Associated Enteropathy: An Uncommon Cause of Chronic Diarrhea.Clinical case reports · 2025Article
- Article
- Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.Case reports in medicine · 2024Article
- Severe spruelike enteropathy and collagenous colitis caused by olmesartan.BMC gastroenterology · 2021Article
- Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.Wiener klinische Wochenschrift · 2019Review
- Chronic Diarrhea Evaluation in the Elderly: IBS or Something Else?Current gastroenterology reports · 2019Review
- Olmesartan-associated severe gastritis and enteropathy.BMJ case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olmesartan, an angiotensin-receptor blocker frequently prescribed for hypertension, has been commercially available since 2002. In 2012, olmesartan-associated enteropathy was described, and the Food and Drug Administration now requires a black-box warning for olmesartan regarding severe diarrhea. The disorder can be life-threatening and often requires hospitalization. We present three cases that represent different aspects of this disorder, as well as some unusual features.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.